Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Published:2018-07-15 Issue:3 Volume:50 Page:691-700
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Nishio Makoto,Kim Dong-Wan,Wu Yi-Long,Nakagawa Kazuhiko,Solomon Benjamin J.,Shaw Alice T.,Hashigaki Satoshi,Ohki Emiko,Usari Tiziana,Paolini Jolanda,Polli Anna,Wilner Keith D.,Mok Tony

Funder

Pfizer Inc

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://e-crt.org/upload/pdf/crt-2017-280.pdf

Reference12 articles.

1. Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment

2. ALK inhibitors in the treatment of advanced NSCLC

3. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

4. ALKin Lung Cancer: Past, Present, and Future

5. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhalable iron redox cycling powered nanoreactor for amplified ferroptosis-apoptosis synergetic therapy of lung cancer;Nano Research;2024-02-01

2. Prognostic factors of resectable anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients: a retrospective analysis based on a single center;Translational Lung Cancer Research;2024-01

3. Dual peptides-modified cationic liposomes for enhanced Lung cancer gene therapy by a gap junction regulating strategy;Journal of Nanobiotechnology;2023-12-09

4. Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review;Cancers;2023-10-11

5. A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer;Cancer Medicine;2023-06-19